Mustafa ÖZBEK, Erman ÇAKAL, Muhammed Erkam SENCAR, Murat ÇALAPKULU, Davut SAKIZ, İlknur ÖZTÜRK ÜNSAL, Sema HEPŞEN, Pınar AKHANLI, Hakan DÜĞER, Bekir UÇAN, Seyit Murat BAYRAM

Fatty acid-binding protein-4 as a biomarker predicting acromegaly-associated diabetes mellitus

Background/aim: The known pathogenesis of diabetes mellitus (DM) in acromegaly is mainly based on growth hormone (GH) and insulin-like growth factor-1 (IGF-1) excess. Fatty acid-binding protein 4 (FABP-4), a novel adipokine, is found to induce insulin resistance and type 2 DM. We aimed to investigate the possible effect of FABP-4 on glucose metabolism in patients with acromegaly. Materials and methods: This case-control study included 28 patients newly diagnosed with acromegaly and 57 healthy volunteers. The patients with acromegaly were classified according to their glycemic status as with DM, prediabetes, and normal glucose tolerance. Anthropometric measurements, laboratory test results, and FABP-4 levels of the subjects were evaluated. Results: Although no difference was observed in FABP-4 levels between acromegaly and control groups, the FABP-4 level was higher in the patients with acromegaly having DM compared to the patients with acromegaly having prediabetes and NGT, and the control group (p = 0.004, p = 0.001, p = 0.004, respectively). Logistic regression analysis suggested that the FABP-4 is an independent predictor of DM in acromegaly (β = 7.382, OR = 38.96, 95% CI: 1.52-5.76, p = 0.018). Conclusion: The FABP-4 may be a helpful predictor of acromegaly-associated DM.Key words: Acromegaly, adipokin, FABP-4, diabetes mellitus

PDF

___

1. Lavrentaki A, Paluzzi A, Wass JAH, Karavitaki N. Epidemiology of acromegaly: review of population studies. Pituitary 2017; 20 (1): 4–9. doi:10.1007/s11102-016-0754-x
2. Mercado M, Ramírez-Rentería C. Metabolic complications of acromegaly. Frontiers of Hormone Research 2018; 49: 20–28. doi:10.1159/000486001
3. Gözü HI, Öztaş D, Güleryüzlü Y, Volkan Ö, Dündar C et al. Evaluation of cardiovascular parameters in acromegalic patients. Turkish Journal of Endocrinology and Metabolism 2007; 11: 1-6
4. Dreval A V, Trigolosova I V, Misnikova I V, Kovalyova YA, Tishenina RS et al. Prevalence of diabetes mellitus in patients with acromegaly. Endocrine Connections 2014; 3 (2): 93–98. doi:10.1530/EC-14-0021
5. Alexopoulou O, Bex M, Kamenicky P, Mvoula AB, Chanson P et al. Prevalence and risk factors of impaired glucose tolerance and diabetes mellitus at diagnosis of acromegaly: a study in 148 patients. Pituitary 2014; 17 (1): 81–89. doi:10.1007/s11102- 013-0471-7
6. Fieffe S, Morange I, Petrossians P, Chanson P, Rohmer V et al. Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry. European Journal of Endocrinology 2011; 164 (6): 877–884. doi:10.1530/EJE-10- 1050
7. Ferraù F, Albani A, Ciresi A, Giordano C, Cannavò S. Diabetes secondary to acromegaly: physiopathology, clinical features and effects of treatment. Frontiers in Endocrinology 2018; 9: 358. doi:10.3389/fendo.2018.00358
8. Olarescu NC, Bollerslev J. The impact of adipose tissue on insulin resistance in acromegaly. Trends in Endocrinology and Metabolism 2016; 27 (4): 226–237. doi:10.1016/j. tem.2016.02.005
9. Trojnar M, Patro-Małysza J, Kimber-Trojnar Ż, LeszczyńskaGorzelak B, Mosiewicz J. Associations between Fatty AcidBinding Protein 4−A proinflammatory adipokine and insulin resistance, gestational and type 2 diabetes mellitus. Cells 2019; 8 (3): 227. doi:10.3390/cells8030227
10. Zhang Y, Zhang H-H, Lu J-H, Zheng S-Y, Long T et al. Changes in serum adipocyte fatty acid-binding protein in women with gestational diabetes mellitus and normal pregnant women during mid- and late pregnancy. Journal of Diabetes Investigation 2016; 7 (5): 797–804. doi:10.1111/jdi.12484
11. Li J-C, Wu D-A, Hou J-S, Subeq Y-M, Chen H-D et al. High serum adipocyte fatty acid binding protein is associated with metabolic syndrome in patients with type 2 diabetes. Journal of Diabetes Research 2016; 2016: 8380279. doi:10.1155/2016/8380279
12. Djoussé L, Gaziano JM. Plasma levels of FABP4, but not FABP3, are associated with increased risk of diabetes. Lipids 2012; 47 (8): 757–762. doi:10.1007/s11745-012-3689-7
13. Katznelson L, Laws ER, Melmed S, Molitch ME, Murad MH et al. Acromegaly: an endocrine society clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism 2014; 99 (11): 3933–3951. doi:10.1210/jc.2014-2700
14. American Diabetes Association. 2. classification and diagnosis of diabetes: standards of medical care in Diabetes-2019. Diabetes Care 2019; 42 (Suppl 1): S13–28. doi:10.2337/ dc19-S002
15. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28 (7): 412–419. doi:10.1007/bf00280883
16. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. World Health Organization Technical Report Series 2000; 894: i–xii, 1–253
17. Lovic D, Narayan P, Pittaras A, Faselis C, Doumas M et al. Left ventricular hypertrophy in athletes and hypertensive patients. Journal of Clinical Hypertension (Greenwich). 2017; 19 (4): 413–417. doi:10.1111/jch.12977
18. Espinosa-de-los-Monteros AL, González B, Vargas G, Sosa E, Mercado M. Clinical and biochemical characteristics of acromegalic patients with different abnormalities in glucose metabolism. Pituitary 2011; 14 (3): 231–235. doi:10.1007/ s11102-010-0284-x
19. Møller N, Jørgensen JOL. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009; 30 (2): 152–177. doi:10.1210/er.2008- 0027
20. Kasayama S, Otsuki M, Takagi M, Saito H, Sumitani S et al. Impaired beta-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clinical Endocrinology 2000; 52 (5): 549–555. doi:10.1046/j.1365-2265.2000.00986.x
21. Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism--novel insights from genomewide studies. FEBS Letters 2010; 584 (15): 3242–3249. doi:10.1016/j.febslet.2010.06.010
22. Garin-Shkolnik T, Rudich A, Hotamisligil GS, Rubinstein M. FABP4 attenuates PPARγ and adipogenesis and is inversely correlated with PPARγ in adipose tissues. Diabetes 2014; 63 (3): 900–911. doi:10.2337/db13-0436
23. Patro-Małysza J, Trojnar M, Kimber-Trojnar Ż, Mierzyński R, Bartosiewicz J, et al. FABP4 in gestational diabetes-association between mothers and offspring. Journal of Clinical Medicine 2019; 8 (3): 285. doi:10.3390/jcm8030285